$SILK
Silk Road Medical Inc Stock $silk

$silk Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000139770219000008 Filed on May 15, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$14.93M	$12.77M	$5.706M
YoY Change	92.2%	123.73%
Cost Of Revenue	$3.697M	$3.339M	$1.934M
YoY Change	54.62%	72.65%
Gross Profit	$11.23M	$9.427M	$3.772M
YoY Change	108.91%	149.92%
Gross Profit Margin	75.23%	73.84%	66.11%
Selling, General & Admin	$14.14M	$13.87M	$6.319M
YoY Change	80.85%	119.43%
% of Gross Profit	125.86%	147.09%	167.52%
Research & Development	$3.113M	$2.707M	$2.100M
YoY Change	33.83%	28.9%
% of Gross Profit	27.72%	28.72%	55.67%
Depreciation & Amortization	$180.0K	$174.0K	$57.00K
YoY Change	157.14%	205.26%
% of Gross Profit	1.6%	1.85%	1.51%
Operating Expenses	$17.25M	$16.57M	$8.419M
YoY Change	70.07%	96.85%
Operating Profit	-$6.017M	-$7.146M	-$4.647M
YoY Change	26.25%	53.78%
Interest Expense	$1.207M	$1.352M	$989.0K
YoY Change	19.39%	36.7%
% of Operating Profit
Other Income/Expense, Net	-$5.333M	-$15.71M	$215.0K
YoY Change	180.98%	-7407.91%
Pretax Income	-$11.96M	-$24.16M	-$5.410M
YoY Change	56.34%	346.58%
Income Tax
% Of Pretax Income
Net Earnings	-$11.96M	-$24.16M	-$5.408M
YoY Change	56.31%	346.71%
Net Earnings / Revenue	-80.11%	-189.24%	-94.78%
Basic Earnings Per Share
Diluted Earnings Per Share	-$388.9K	-$799.2K	-$179.0K
COMMON SHARES
Basic Shares Outstanding	30.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$118.2M	$15.50M
YoY Change
Cash & Equivalents	$118.2M	$15.51M	$29.02M
Short-Term Investments
Other Short-Term Assets	$3.200M	$1.400M
YoY Change
Inventory	$8.963M	$8.056M
Prepaid Expenses
Receivables	$5.417M	$4.096M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$135.9M	$29.05M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$2.743M	$2.846M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.723M	$3.982M
YoY Change
Total Long-Term Assets	$6.776M	$9.616M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$135.9M	$29.05M
Total Long-Term Assets	$6.776M	$9.616M
Total Assets	$142.7M	$38.67M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.189M	$3.134M
YoY Change
Accrued Expenses	$8.299M	$721.0K
YoY Change
Deferred Revenue	$257.0K
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.488M	$10.79M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$44.69M	$44.60M
YoY Change
Other Long-Term Liabilities	$4.097M	$4.469M
YoY Change
Total Long-Term Liabilities	$48.79M	$49.07M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.488M	$10.79M
Total Long-Term Liabilities	$48.79M	$49.07M
Total Liabilities	$58.28M	$91.48M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$175.2M	-$163.3M
YoY Change
Common Stock	$31.00K	$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$84.38M	-$158.1M	-$103.5M
YoY Change
Total Liabilities & Shareholders Equity	$142.7M	$38.67M
YoY Change

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$11.96M	-$24.16M	-$5.408M
YoY Change	56.31%	346.71%
Depreciation, Depletion And Amortization	$180.0K	$174.0K	$57.00K
YoY Change	157.14%	205.26%
Cash From Operating Activities	-$9.380M	-$8.620M	-$4.650M
YoY Change	77.32%	85.38%
INVESTING ACTIVITIES
Capital Expenditures	-$90.00K	$117.0K	$455.0K
YoY Change	-83.33%	-74.29%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$90.00K	-$117.0K	-$455.0K
YoY Change	-83.33%	-74.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$375.0K	$284.0K
YoY Change		32.04%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	112.2M	-$744.0K	$284.0K
YoY Change	74706.67%	-361.97%
NET CHANGE
Cash From Operating Activities	-9.380M	-$8.620M	-$4.650M
Cash From Investing Activities	-90.00K	-$117.0K	-$455.0K
Cash From Financing Activities	112.2M	-$744.0K	$284.0K
Net Change In Cash	102.7M	-$9.481M	-$4.821M
YoY Change	-1908.8%	96.66%
FREE CASH FLOW
Cash From Operating Activities	-$9.380M	-$8.620M	-$4.650M
Capital Expenditures	-$90.00K	$117.0K	$455.0K
Free Cash Flow	-$9.290M	-$8.737M	-$5.105M
YoY Change	95.58%	71.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001397702
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	Silk Road Medical Inc
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	29879220	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1135310	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1135310	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1386615	shares
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5408000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24158000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
CY2019Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2019Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.3704
CY2018Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21233190	shares
CY2019Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21238105	shares
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30672125	shares
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15509000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-103453000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163269000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-2000	USD
CY2018Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	23000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-5408000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10792000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-139111000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8838000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24990000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4096000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4520000	USD
CY2019Q1	us-gaap	Inventory Net InventoryNet	8056000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	5744000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1391000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1408000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	29052000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	36662000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2846000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2880000	USD
CY2019Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6460000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1029000	USD
CY2019Q1	us-gaap	Assets Assets	38668000	USD
CY2018Q4	us-gaap	Assets Assets	40881000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3134000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1252000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7658000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7586000	USD
CY2019Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	44597000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	44201000	USD
CY2019Q1	silk	Preferred Stock Warrant Liability PreferredStockWarrantLiability	31803000	USD
CY2018Q4	silk	Preferred Stock Warrant Liability PreferredStockWarrantLiability	16091000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4285000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1069000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	91477000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	70199000	USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	105265000	USD
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	105235000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5194000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4557000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-24158000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7146000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	241000	USD
CY2019Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	15712000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4647000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	739308	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-134553000	USD
CY2018Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-216000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	375000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	52000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	13000	USD
CY2019Q1	silk	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	0	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-158074000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-134553000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38668000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40881000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12766000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5706000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3339000	USD
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1934000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	9427000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	3772000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2707000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2100000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13866000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6319000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	16573000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	8419000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	1352000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	989000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15712000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	215000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-24158000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-5408000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-20.12
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.31
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1200719	shares
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	21000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-24158000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-158074000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-98578000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	57000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-5408000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	174000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	262000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	162000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	284000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	164000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	870000	USD
CY2018Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2019Q1	silk	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	162000	USD
CY2019Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	471000	USD
CY2018Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	386000	USD
CY2019Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	313000	USD
CY2018Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	278000	USD
CY2019Q1	us-gaap	Inventory Write Down InventoryWriteDown	27000	USD
CY2018Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-110000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2012000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2339000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	433000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-16000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	387000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	651000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-17000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2287000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-244000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	52000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-897000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1069000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8620000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4650000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	117000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	455000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-117000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-455000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	375000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	284000	USD
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	30000	USD
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1149000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-744000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	284000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9481000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4821000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25300000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33841000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15819000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29020000	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	580000	USD
CY2019Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	22000	USD
CY2018Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	90000	USD
CY2019Q1	silk	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	1204000	USD
CY2018Q1	silk	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3982000	USD
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1200719	shares
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to the common stock valuation and related stock-based compensation, the valuation of the redeemable convertible preferred stock warrants, the valuation of deferred tax assets, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and the reserves for sales returns. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div>
CY2019Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000	USD
CY2019Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;font-weight:bold;">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">The Company’s policy is to invest in money market funds, which are classified as cash equivalents on the condensed consolidated balance sheet. The Company's cash are held in Company accounts at two financial institutions and such amounts may exceed federally insured limits. The Company's money market funds are invested in highly rated money market funds. </span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">The Company’s accounts receivable are due from a variety of health care organizations in the United States. At </span><span style="font-family:Arial;font-size:10pt;color:#000000;">March 31, 2019</span><span style="font-family:Arial;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;color:#000000;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;">no</span><span style="font-family:Arial;font-size:10pt;color:#000000;"> customer represented 10% or more of the Company’s accounts receivable. For the three months ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;">March 31, 2019</span><span style="font-family:Arial;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;">March 31, 2018</span><span style="font-family:Arial;font-size:10pt;color:#000000;">, there were </span><span style="font-family:Arial;font-size:10pt;color:#000000;">no</span><span style="font-family:Arial;font-size:10pt;color:#000000;"> customers that represented 10% or more of revenue. </span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">The Company manufactures certain of its commercial products in-house. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE stent. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in </span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.</span></div>
CY2019Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2585000	USD
CY2018Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	950000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3982000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	721000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4469000	USD
CY2019Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	131000	USD
CY2018Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-24158000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-5408000	USD
CY2017	silk	Debt Instrument Covenant Minimum Net Revenue Amount DebtInstrumentCovenantMinimumNetRevenueAmount	5000000	USD
CY2018	silk	Debt Instrument Covenant Minimum Net Revenue Amount DebtInstrumentCovenantMinimumNetRevenueAmount	15000000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	739308	shares
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-20.12
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.31
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28051854	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28337489	shares
CY2019Q1	silk	Debt Instrument Liquidity Covenant Term DebtInstrumentLiquidityCovenantTerm	P90D
CY2019Q1	us-gaap	Long Term Debt LongTermDebt	44597000	USD
CY2019Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	16091000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-15712000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	31803000	USD
CY2019Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2147000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1054000	USD
CY2019Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5909000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4690000	USD
CY2019Q1	us-gaap	Inventory Net InventoryNet	8056000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	5744000	USD
CY2019Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
CY2018Q3	silk	Debt Maximum Borrowing Capacity DebtMaximumBorrowingCapacity	15000000	USD
CY2019Q1	silk	Debt Instrument Covenant Maximum Liquidity Amount DebtInstrumentCovenantMaximumLiquidityAmount	3000000	USD
CY2016	silk	Debt Instrument Covenant Minimum Net Revenue Amount DebtInstrumentCovenantMinimumNetRevenueAmount	1000000	USD
CY2019Q1	silk	Long Term Debt Unpaid Interest LongTermDebtUnpaidInterest	18841000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3820000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	712000	USD
CY2019Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	174000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4285000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4997000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1066000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3771000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	52510000	USD
CY2019Q1	silk	Long Term Debt Gross Before Accretion Of Closing Fees LongTermDebtGrossBeforeAccretionOfClosingFees	62654000	USD
CY2019Q1	silk	Long Term Debt Accretion Of Closing Fees LongTermDebtAccretionOfClosingFees	958000	USD
CY2019Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	63612000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	760000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1037000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	2696000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	3677000	USD
CY2019Q1	us-gaap	Long Term Debt LongTermDebt	44597000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	217000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	193000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1096000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1127000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	904000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5990000	USD
CY2019Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	28248103	shares
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	993000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4997000	USD
CY2019Q1	us-gaap	Purchase Obligation PurchaseObligation	2855100	USD
CY2019Q1	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2019Q1	silk	Common Stock Vote Per Share CommonStockVotePerShare	1	vote
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1920000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	5999000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1002000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1002000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1031000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1044000	USD
CY2019Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	24069615	shares
CY2019Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	21238105	shares
CY2019Q1	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	121174000	USD
CY2019Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	105265000	USD
CY2018Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	24069615	shares
CY2018Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	21233190	shares
CY2018Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	121144000	USD
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	105235000	USD
CY2019Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	USD
CY2019Q1	silk	Convertible Preferred Stock Termsof Conversion Share Price ConvertiblePreferredStockTermsofConversionSharePrice	18.31
CY2019Q1	silk	Convertible Preferred Stock Termsof Conversion Offering Proceeds ConvertiblePreferredStockTermsofConversionOfferingProceeds	50000000	USD
CY2019Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	29879220	shares
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1386615	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.29
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	251305	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.50
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	7387	shares
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y3M3D
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	7387	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.56
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	28499408	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	30602000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2461000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.00
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	57889	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4364377	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.79
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M9D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	33132000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	0	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	32950	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	32950	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	32326	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4138635	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.00
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M3D
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	30602000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2451044	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.70
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M9D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	21195000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4138635	shares
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	262000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	162000	USD
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2433000	USD
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y14D

Files In Submission

Name	View Source	Status
0001397702-19-000008-index-headers.html	Edgar Link	pending
0001397702-19-000008-index.html	Edgar Link	pending
0001397702-19-000008.txt	Edgar Link	pending
0001397702-19-000008-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
q12019exhibit311.htm	Edgar Link	pending
q12019exhibit312.htm	Edgar Link	pending
q12019exhibit321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
silk-20190331.xsd	Edgar Link	pending
silk-20190331_cal.xml	Edgar Link	unprocessable
silk-20190331_def.xml	Edgar Link	unprocessable
silk-20190331_lab.xml	Edgar Link	unprocessable
silk-20190331_pre.xml	Edgar Link	unprocessable
silkroad10-q331.htm	Edgar Link	pending
silkroad10-q331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SILK
Silk Road Medical Inc Stock $silk

2019 Q2 Form 10-Q Financial Statement

#000139770219000008 Filed on May 15, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILK Silk Road Medical Inc Stock $silk

2019 Q2 Form 10-Q Financial Statement

#000139770219000008 Filed on May 15, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILK
Silk Road Medical Inc Stock $silk